Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Imdevimab (DVV00305)

Host species:Human
Isotype:IgG1, lambda
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DVV00305

Expression system

Mammalian Cells

Species reactivity

SARS-CoV-2 (2019-nCoV)

Host species

Human

Isotype

IgG1, lambda

Clonality

Monoclonal

Target

Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2

Concentration

2.9 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P0DTC2

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

REGN-10987, REGN10987, CAS: 2415933-40-1

Clone ID

Imdevimab

Data Image
  • SDS-PAGE
    SDS PAGE for Imdevimab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Imdevimab, PMID: 33226741

An EUA for casirivimab and imdevimab for COVID-19, PMID: 33451174

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, PMID: 33332778

COVID-19 vaccines: The status and perspectives in delivery points of view, PMID: 33359141

Imdevimab, PMID: 34283431

Antibodies to watch in 2021, PMID: 33459118

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, PMID: 33037066

Casirivimab, PMID: 33226742

Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic, PMID: 33253920

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents, PMID: 33388760

Casirivimab-imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: An Early Experience, PMID: 33724242

Casirivimab, PMID: 34283490

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia, PMID: 34194882

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, PMID: 34435337

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019, PMID: 34279629

Neutralizing Antibody Therapeutics for COVID-19, PMID: 33916927

In Translation: FcRn across the Therapeutic Spectrum, PMID: 33802650

Monoclonal antibodies for treating COVID-19, PMID: 33597176

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19, PMID: 34347950

COVID-19: potential therapeutics for pediatric patients, PMID: 34458951

Real world utilization of REGEN-COV2 at a community hospital, PMID: 34364110

Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19, PMID: 33497123

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options, PMID: 34071185

Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19, PMID: 34393218

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus, PMID: 33917138

Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention, PMID: 34159344

Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2, PMID: 34422699

Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro, PMID: 34223909

An EUA for bamlanivimab and etesevimab for COVID-19, PMID: 33830966

An EUA for sotrovimab for treatment of COVID-19, PMID: 34181630

The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5, PMID: 33758124

Post Acute Coronavirus (COVID-19) Syndrome, PMID: 34033370

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2, PMID: 33893398

Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany, PMID: 34244967

An update to monoclonal antibody as therapeutic option against COVID-19, PMID: 33585808

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies, PMID: 34201767

Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report, PMID: 34405092

Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions, PMID: 34059561

Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins, PMID: 34006961

Monoclonal Antibodies: Medical Uses for the Prevention and Treatment of Disease, PMID: 33861166

Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience, PMID: 34166513

Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection, PMID: 34159343

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients, PMID: 34258319

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, PMID: 33495308

Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review, PMID: 34157890

A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities, PMID: 33619724

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization, PMID: 34034784

Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants, PMID: 34291118

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia, PMID: 34332085

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines, PMID: 33724631

Datasheet

Document Download

Research Grade Imdevimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Imdevimab [DVV00305]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only